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OBJECTIVE: This study aims to describe the distributions
of lipid lowering and attainment of National Cholesterol
Education Panel goals and apply these distributions to
pharmacoeconomic models for specific populations.
METHODS: Lipid results and costs from a series of
treat-to-target studies of statins (atorvastatin, fluvastatin,
lovastatin, pravastatin, and simvastatin) were used to es-
timate distributions of lipid-lowering effects and cost for
patients.
RESULTS: Almost 1000 patients were enrolled in one of
three trials: patients with risk factors for coronary heart
disease (CHD) in the United States, CHD in the United
States, and CHD or peripheral vascular disease (PVD) in
Europe. Lipid-lowering effects are not normally distrib-
uted and are not consistent among statins. Results for
two statins were skewed right and results for three statins
were skewed left. As a result, costs associated with lipid-
lowering treatment are not normally distributed and are
not equal among statins.
CONCLUSIONS: Models based upon clinical and trials
and associated pharmacoeconomic analyses may be biased
if they use only published data without an understanding
of the underlying distributions of these data. In a set of
populations with higher than average lipid levels (lower
than average lipid levels), models that rely on means from
published studies would underestimate (overestimate) the
differences among statins.
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DP1
EFFECT OF DEMOGRAPHICS ON THE COST 
OF PHARMACEUTICALS IN A PRIVATE 
THIRD-PARTY PRESCRIPTION PROGRAM
Momin SR, Larrat EP, Harlow LL
University of Rhode Island, Kingston, RI, USA
OBJECTIVES: The primary objective of this study was to
compare variance in cost of pharmaceuticals explained
by demographic variables with variance explained by
plan-characteristics within various therapeutic categories
using prescription claims data. The secondary objective
was to examine differences in utilization among demo-
graphic variables after controlling for covariates.
METHODS: Data were obtained from 1996 prescription
claims information for the commercial population ad-
ministered by a Rhode Island–based PBM. There were
29,211 subscribers representing 64,815 enrollees (mean
age 31.5) eligible during 1996. Subscribers were mainly
employed in health (39.8%), sales and services (17.7%),
and manufacturing (10.3%). Six therapeutic categories
were analyzed. Statistical analyses utilizing multiple re-
gression and analysis-of-covariance were performed.
RESULTS: Plan-characteristics out-performed demographic
variables 16-fold for all drug categories combined in ex-
plaining variance in cost of pharmaceuticals. Significant
differences (p  0.0001) in utilization were found among
demographic variables after controlling for average whole-
sale price and days supply.
CONCLUSIONS: The results obtained in this study have
practical significance in the determination of capitation
rates when utilization history of prospective members is un-
available. In this situation, PBMs may have to set capita-
tion rates based solely on eligibility data. PBMs contract
with commercial clients to provide pharmacy benefits to
their employees irrespective of their occupation. Significant
differences in utilization among the members based on
place of employment suggest that benefit managers should
consider differentiating capitation rates according to their
clients’ businesses. Finally, this study indicated that com-
mercial members residing in Tennessee had the lowest level
of drug utilization among all states evaluated. The fact that
one PBM manages over 80% of the TennCare prescription
program along with a significant commercial client base
suggests that “spillover-effect” may exist.
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OBJECTIVE: Hospitalization is the single greatest cost in
the treatment of asthma. Various factors, such as type of
healthcare insurance, may be related to asthma hospital-
ization rates. This study assessed the hospitalization rates
for asthmatics subsequent to an emergency room (ER)
visit among payer types.
METHODS: Medical claims from the Premier PCD data-
base were screened to identify adults (ages 18–65) visit-
ing an ER for treatment of asthma (ICD-9-CM: 493)
from October 1, 1996 to September 30, 1997. Subjects
were then classified into two groups: ER only and ER
and hospitalization. Payers identified from each claim
were grouped into these categories: Managed Care, In-
demnity Plans, Medicaid, Medicare, and Self-Pay.
RESULTS: Of the 2738 patients who met the inclusion
criteria, only 773 (28%) required hospitalization. Self-
Pay patients were the least likely to be hospitalized
(12.6% hospitalization rate) while Indemnity and Man-
aged Care patients were hospitalized at a rate of 23.4%
and 33.3%, respectively. After controlling for age, race,
gender, and comorbidities, Indemnity patients were ap-
proximately 65% as likely to be hospitalized as Managed
Care patients (OR  0.650; 95% CI 0.493–0.856). Of
the hospitalized patients, the Self-Pay patients had the
shortest hospital stay and lowest total cost (2.98 days,
$2417.72). Managed Care patients had lower total costs
and shorter hospital stays than Indemnity patients, how-
ever the differences among the groups were not signifi-
cant. No significant differences in mean age or APR-DRG
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severity were observed between hospitalized Managed
Care patients or Indemnity patients.
CONCLUSIONS: Higher hospitalization rates was ob-
served in the Indemnity patients and may be the factor for
the higher overall asthma costs seen in this payer group.
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USING SIMULATION MODELING TECHNIQUES 
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OBJECTIVE: The purpose of the study was to evaluate
the clinical and economic impact of alternative decision
criteria in the management of the waiting list for liver
transplantation. The impact of changes in the timing of
transplantation for the average estimated net life expect-
ancy of the cohort studied and the overall cost-effective-
ness of the transplantation program at one London cen-
ter were investigated.
METHODS: A discrete event simulation model was de-
veloped to reflect the pattern and timing of care for pa-
tients accepted to the liver transplantation program. A
subsidiary simulation model was also developed to reflect
the pattern and timing of care received for patients re-
jected for liver transplantation. The models were con-
structed to predict changes in the net length of survival
(i.e., predicted survival with transplantation versus survival
without transplantation) and resources used for individual
patients according to the time at which transplantation ac-
tually occurred, and according to alternative times at which
transplantation may have occurred had the waiting list
been managed differently.
RESULTS: Using a 5-year time horizon the total cost per
life-year gained of the liver transplantation program was
£66,146 (CI £54,236–£75,688) using the current selec-
tion policy. It was found that the total cost per life-year
gained could be reduced by as much as 20% (£52,917,
CI £43,731–£59,298) if the less severely ill patients no
longer received priority for a donor organ.
CONCLUSIONS: The pursuit of efficiency in the provi-
sion of liver transplantation also needs to be reconciled
with the important issues of equity and fairness in donor
organ allocation. However, the results of this study sug-
gest that the overall cost-effectiveness of the liver trans-
plantation program could be improved if the current selec-
tion policy were modified to take account of the reduced
chances of success of the more severely ill patients.
DP4
USING COST OF ILLNESS STUDIES IN 
HEALTHCARE POLICY-MAKING
Bloom BS, Bruno D, Kahn A, Maman DY
University of Pennsylvania, Philadelphia, PA, USA
Cost of illness studies have two main uses: to measure
baseline outcomes and changes over time as a function of
changing inputs, and to generate new research hypotheses.
OBJECTIVES: To evaluate the usefulness of cost of ill-
ness studies by testing the likely validity of results.
METHODS: We reviewed all English-language, peer-
reviewed, US studies of specified diagnoses published 1
January 1985 to 31 December 1998. Studies were ob-
tained from MEDLINE and other computerized searching
systems. Direct and indirect costs were adjusted to 1992
dollars for sector-specific (e.g., hospital) inflation since
year of the study. Additional adjustments were made by
diagnosis for technological innovations. Cost comparisons
were made among multiple studies for the same illness.
RESULTS: Of the 1556 studies identified, only 179 met all
inclusion criteria. By diagnosis, cost of illness varied 2- to
10-fold even after adjustments for inflation and effects of
new technology. Such large, mainly nonsystematic, varia-
tions were found among all sectors of direct and indirect
costs. Large variations were due primarily to inconsistent
cost, resource and category definitions, methodology, and
data sources—whether or not study results were derived
nationally or based on population samples of disease inci-
dence and prevalence. The latter studies usually showed
substantially larger annual cost estimates and greater vari-
ation than the former.
CONCLUSION: Cost of illness studies are now of uncer-
tain a priori usefulness. Criteria need to be developed to
construct such studies so that they can be useful policy
and planning tools.
